Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2019’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acadia Pharmaceuticals Inc

Actinogen Medical Ltd

AcuraStem Inc

Adamed Sp zoo

ADEL Inc

AgeneBio Inc

Aibios Co Ltd

Alector Inc

Allergan Plc

Alterity Therapeutics Ltd

Anavex Life Sciences Corp

Annovis Bio Inc

Asceneuron SA

Axon Neuroscience SE

Axovant Gene Therapies Ltd

Biogen Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim International GmbH

Bolder Biotechnology Inc

Cennerv Pharma (S) Pte Ltd

Cortice Biosciences Inc

Daewoong Pharmaceutical Co Ltd

Denali Therapeutics Inc

EIP Pharma LLC

Eisai Co Ltd

Eli Lilly and Co

Ensol Biosciences Inc

Enterin Inc

EVER Neuro Pharma GmbH

Galimedix Therapeutics Ltd

Gismo Therapeutics Inc

Guangzhou Magpie Pharmaceutical Co Ltd

GW Pharmaceuticals Plc

HanAll Biopharma Co Ltd

Hyundai Pharmaceutical Co Ltd

Immungenetics AG

ImStar Therapeutics Inc

Inhibikase Therapeutics Inc

IntraBio Ltd

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

iQure Pharma Inc

IRLAB Therapeutics AB

Johnson & Johnson

Kogenix Therapeutics Inc

LA Cell Inc

Lachesis Biosciences Ltd

Luye Pharma Group Ltd

MediPost Co Ltd

MGC Pharmaceuticals Ltd

Neuraltus Pharmaceuticals Inc

Neurimmune Holding AG

Neurodyn Cognition Inc

NeuroScientific Biopharmaceuticals Ltd

NLS Pharma Group

Novartis AG

Oryzon Genomics SA

Otsuka Holdings Co Ltd

P2D Inc

Pacific Northwest Biotechnology LLC

Park Active Molecules

Passage Bio Inc

Plico Biotech Inc

Prevail Therapeutics Inc

ProMIS Neurosciences Inc

Prothena Corp Plc

Psy Therapeutics Inc

Rodin Therapeutics Inc

SanBio Inc

Sinfonia Biotherapeutics Inc

Stemedica Cell Technologies Inc

Sun Pharma Advanced Research Company Ltd

SyneuRx International Corp

TauRx Therapeutics Ltd

Theranexus SAS

UniQure NV

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

WhanIn Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Involved in Therapeutics Development

Argenx SE

CSL Ltd

GeNeuro SA

Immupharma Plc

Momenta Pharmaceuticals Inc

Octapharma AG

Pfizer Inc

Takeda Pharmaceutical Co Ltd

Teijin Pharma Ltd

UCB SA

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Profiles

efgartigimod alfa Drug Profile

Product Description

Mechanism Of Action

R&D Progress

forigerimod acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hyaluronidase (recombinant, human) + immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06755347 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temelimab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Discontinued Products

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Development Milestones

Featured News & Press Releases

Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045

Jun 15, 2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

Apr 20, 2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

Mar 16, 2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Jan 26, 2018: CHMP Recommends Extension of Indications for Hizentra

Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Sep 14, 2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

Jul 11, 2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed

Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy

Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Dementia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Dementia – Pipeline by Acadia Pharmaceuticals Inc, H2 2019

Dementia – Pipeline by Actinogen Medical Ltd, H2 2019

Dementia – Pipeline by AcuraStem Inc, H2 2019

Dementia – Pipeline by Adamed Sp zoo, H2 2019

Dementia – Pipeline by ADEL Inc, H2 2019

Dementia – Pipeline by AgeneBio Inc, H2 2019

Dementia – Pipeline by Aibios Co Ltd, H2 2019

Dementia – Pipeline by Alector Inc, H2 2019

Dementia – Pipeline by Allergan Plc, H2 2019

Dementia – Pipeline by Alterity Therapeutics Ltd, H2 2019

Dementia – Pipeline by Anavex Life Sciences Corp, H2 2019

Dementia – Pipeline by Annovis Bio Inc, H2 2019

Dementia – Pipeline by Asceneuron SA, H2 2019

Dementia – Pipeline by Axon Neuroscience SE, H2 2019

Dementia – Pipeline by Axovant Gene Therapies Ltd, H2 2019

Dementia – Pipeline by Biogen Inc, H2 2019

Dementia – Pipeline by BioXcel Therapeutics Inc, H2 2019

Dementia – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Dementia – Pipeline by Bolder Biotechnology Inc, H2 2019

Dementia – Pipeline by Cennerv Pharma (S) Pte Ltd, H2 2019

Dementia – Pipeline by Cortice Biosciences Inc, H2 2019

Dementia – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Dementia – Pipeline by Denali Therapeutics Inc, H2 2019

Dementia – Pipeline by EIP Pharma LLC, H2 2019

Dementia – Pipeline by Eisai Co Ltd, H2 2019

Dementia – Pipeline by Eli Lilly and Co, H2 2019

Dementia – Pipeline by Ensol Biosciences Inc, H2 2019

Dementia – Pipeline by Enterin Inc, H2 2019

Dementia – Pipeline by EVER Neuro Pharma GmbH, H2 2019

Dementia – Pipeline by Galimedix Therapeutics Ltd, H2 2019

Dementia – Pipeline by Gismo Therapeutics Inc, H2 2019

Dementia – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019

Dementia – Pipeline by GW Pharmaceuticals Plc, H2 2019

Dementia – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Dementia – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019

Dementia – Pipeline by Immungenetics AG, H2 2019

Dementia – Pipeline by ImStar Therapeutics Inc, H2 2019

Dementia – Pipeline by Inhibikase Therapeutics Inc, H2 2019

Dementia – Pipeline by IntraBio Ltd, H2 2019

Dementia – Pipeline by INVENT Pharmaceuticals Inc, H2 2019

Dementia – Pipeline by Ionis Pharmaceuticals Inc, H2 2019

Dementia – Pipeline by iQure Pharma Inc, H2 2019

Dementia – Pipeline by IRLAB Therapeutics AB, H2 2019

Dementia – Pipeline by Johnson & Johnson, H2 2019

Dementia – Pipeline by Kogenix Therapeutics Inc, H2 2019

Dementia – Pipeline by LA Cell Inc, H2 2019

Dementia – Pipeline by Lachesis Biosciences Ltd, H2 2019

Dementia – Pipeline by Luye Pharma Group Ltd, H2 2019

Dementia – Pipeline by MediPost Co Ltd, H2 2019

Dementia – Pipeline by MGC Pharmaceuticals Ltd, H2 2019

Dementia – Pipeline by Neuraltus Pharmaceuticals Inc, H2 2019

Dementia – Pipeline by Neurimmune Holding AG, H2 2019

Dementia – Pipeline by Neurodyn Cognition Inc, H2 2019

Dementia – Pipeline by NeuroScientific Biopharmaceuticals Ltd, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Dementia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports